Olanzapine/Zonisamide

奥氮平/唑尼沙胺

Report date: 2022/07/04 19:38:02

Base Information

Drug NameOlanzapine/Zonisamide
Drug Alias NameZonisamide/Olanzapine唑尼沙胺+奥氮平唑尼沙胺奥氮平Olanzapine and ZonisamideZonisamide and Olanzapine +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D1 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 2 (5-HT2) receptor antagonists +[6] 
TargetsDopamine D1 receptorDopamine D2 receptorSerotonin 2 (5-HT2) receptor +[6] 
Therapy Area/IndicationsSchizophreniaPsychotic Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes OlanzapineZonisamide
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOrexigen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOrexigen Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSchizophreniaPsychotic Disorders

Other Information

ATC CodeN/A
Related LinksN/A